Clinuvel PharmaceuticalsASX:CUV +3.60%81 Current Ratio is 14.64 as of Dec. 2025, which is 39% above its 10-year median of 10.55. GuruFocus rates ASX:CUV with a GF Score™ of 81/100 and a GF Value™ of A$17.71 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 86.47% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Clinuvel Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 14.64.
Clinuvel Pharmaceuticals has a current ratio of 14.64. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Current Ratio or its related term are showing as below:
ASX:CUV'
s Current Ratio Range Over the Past 10 Years
Min: 6.86 Med: 10.55 Max: 17.54
Current: 14.64
During the past 13 years, Clinuvel Pharmaceuticals's highest Current Ratio was 17.54. The lowest was 6.86. And the median was 10.55.
ASX:CUV's Current Ratio is ranked better than 86.47% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs ASX:CUV: 14.64
Clinuvel Pharmaceuticals (ASX:CUV) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Clinuvel Pharmaceuticals Current Ratio Related Terms
Clinuvel Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (ASX:CUV) has a Current Ratio of 14.64 as of Dec. 2025. This is 39% above median its historical median of 10.55. Over the past decade, Clinuvel Pharmaceuticals' Current Ratio has ranged from 6.86 to 17.54. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #191 out of 1412 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Clinuvel Pharmaceuticals' Current Ratio too high?
Clinuvel Pharmaceuticals' current Current Ratio of 14.64 is 39% above median its 10-year median of 10.55. Over the past 10 years, this metric has ranged from a low of 6.86 to a high of 17.54. The Biotechnology industry median Current Ratio is 3.89. Clinuvel Pharmaceuticals' value of 14.64 is 276.3% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #191 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #191 out of 1412 companies for Current Ratio. This places Clinuvel Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Clinuvel Pharmaceuticals' value of 14.64 is 276.3% above this benchmark. Historically, Clinuvel Pharmaceuticals' own Current Ratio has ranged from 6.86 to 17.54 over the past decade. While the company's 10-year median is 10.55 vs. the industry median of 3.89, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Current Ratio of 14.64 is 276.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Current Ratio is 14.64, which is 39% above median its own 10-year median of 10.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.71, compared to a current price of A$10.35 — trading 41.6% below its estimated fair value. The current Current Ratio is 14.64, which is 39% above median its 10-year median of 10.55 and 276.3% above the Biotechnology industry median of 3.89. Clinuvel Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Current Ratio is 14.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.35 is trading 41.6% below its estimated GF Value™ of A$17.71.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Current Ratio: 14.64 (39% above median its 10-year median of 10.55)
GF Value™: A$17.71 vs. price of A$10.35 (41.6% below fair value)
Industry Position: 276.3% above the Biotechnology median (#191 of 1412)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
81GF Score
Get the complete analysis for ASX:CUV
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
